<DOC>
	<DOC>NCT02348697</DOC>
	<brief_summary>Non-interventional study to evaluate safety and efficacy of NOVOCART 3D in adult and adolescent patients with full thickness cartilage defects after the treatment with NOVOCART 3D.</brief_summary>
	<brief_title>Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects</brief_title>
	<detailed_description>A 36-month post treatment follow up of adverse and serious adverse effects as well as the measurement of efficacy with the International Knee Documentation Committee (IKDC) Score.</detailed_description>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>Male and female adult patients Children and adolescents with closed epiphysial plate Defect size ≥2.5 and ≤10 cm2 postdebridement Localized full thickness articular cartilage defect of the knee (Grade 3 &amp; 4 International Cartilage Repair Society (ICRS) classification) Radiologically apparent degenerative joint disease in the target knee as determined by Kellgren and Lawrence grade &gt;2 More than 2 defects or 2 corresponding lesions Ankylosis Arthrofibrosis Diffuse chondromalacia Total/subtotal resected meniscus Insufficient Ligament guidance Patella malignement Inflammatory joint disease General cartilage degeneration or increased joint deterioration Cancer, present or within the last 5 years Primary treatment in children and adolescents with open epiphysial plate Chronical infection diseases Untreated coagulation disorder Pregnancy and lactating Known history of allergies against ingredients of NOVOCART® 3D</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cartilage Defect in the Knee</keyword>
	<keyword>MACT</keyword>
</DOC>